On Target Podcast

Jack Meehan, co-founder and analyst at Operon Research, talks about the where the diagnostics industry is now and where he sees it heading.

Mirna Jarosz, CEO of LiquidCellDx, explains how her company's liquid biopsy captures information about the tumor microenvironment, providing critical treatment guidance.

Hamed Amini, CEO and co-founder of Hepta Bio, tells us how his company's liquid biopsy can diagnose liver fibrosis due to MASH, identifying patients who are treatment candidates.

Ajit Singh, CEO of Harbinger Health, explains how his company's diagnostic determines whether a patient with nonspecific clinical signs has cancer.

Mike Klein, CEO of Genomenon, explains how the company combines AI-powered technology with expert human curation to mine the global scientific literature for evidence describing genetic variants.

Bob Wassman, chief medical officer and executive vice president of clinical affairs at MARABio, explains how testing for maternal auto-antibodies can drive early autism diagnosis and treatment.

Suchi Saria, founder and CEO of Bayesian Health, tells us about her company's sepsis-detection system - and how to successfully bring such a system into the clinic.

Connie Lehman, founder and CEO of Clairity, shares how AI-driven insights can improve early detection, personalize screening, and ultimately change the future of breast-cancer care.

Madhuri Hegde, SVP and CSO of Revvity, discusses how her company leverages partnerships and broad expertise in both life sciences and diagnostics to solve patient problems.

Janet Woodcock, distinguished FDA veteran and past deputy commissioner of the agency, gives us her take on AI, companion diagnostics, drugs for rare diseases, and how to earn trust for new technology.